Cited by 86Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Neuropathologic assessment of participants in two multi‐center longitudinal observational studies: The A lzheimer D isease N euroimaging I nitiative (ADNI) and the D ominantly I nherited A lzheimer N etwork (DIAN)

Open access
Cairns, Nigel J., Perrin, Richard J., Franklin, Erin E., Carter, Deborah, Vincent, Benjamin, Xie, Mingqiang, Bateman, Randall J., Benzinger, Tammie +8 more·2015·Neuropathology

Abstract

It has been hypothesized that the relatively rare autosomal dominant A lzheimer disease (ADAD) may be a useful model of the more frequent, sporadic, late‐onset AD (LOAD). Individuals with ADAD have a predictable age at onset and the biomarker profile of ADAD participants in the preclinical stage may be used to predict disease progression and clinical onset. However, the extent to which the pathogenesis and neuropathology of ADAD overlaps with that of LOAD is equivocal. To address this uncertainty, two multicenter longitudinal observational studies, the A lzheimer D isease N euroimaging I nitiative (ADNI) and the D ominantly I nherited A lzheimer N etwork (DIAN), leveraged the expertise and resources of the existing K night A lzheimer D isease R esearch C enter (ADRC) at W ashington U niversity S chool of M edicine, S t. L ouis, M issouri, USA, to establish a N europathology C ore (NPC). The ADNI/DIAN‐NPC is systematically examining the brains of all participants who come to autopsy at the 59 ADNI sites in the USA and C anada and the 14 DIAN sites in the USA (eight), A ustralia (three), UK (one) and G ermany (two). By 2014, 41 ADNI and 24 DIAN autopsies (involving nine participants and 15 family members) had been performed. The autopsy rate in the ADNI cohort in the most recent year was 93% (total since NPC inception: 70%). In summary, the ADNI/DIAN NPC has implemented a standard protocol for all sites to solicit permission for brain autopsy and to send brain tissue to the NPC for a standardized, uniform and state‐of‐the‐art neuropathologic assessment. The benefit to ADNI and DIAN of the implementation of the NPC is very clear. The NPC provides final “gold standard” neuropathological diagnoses and data against which the antecedent observations and measurements of ADNI and DIAN can be compared.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/neup.12205

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Studies indicate that familial and sporadic Alzheimer's disease have very similar pathogenesis, pathophysiology, and progression.

    “Studies have indicated that the pathogenesis of familial and sporadic Alzheimer’s disease are very similar and share similar pathophysiology and progression36–39.”
  • FAD shows significantly different development of associated neuropathology such as TDP-43 and argyrophilic grain disease compared to sAD; in the ADNI sAD cohort the latter two pathologies occurred in about 20% of subjects, while in the FAD DIAN cohort these pathologies were absent.

    “In addition, FAD shows significantly different development of associated neuropathology such as TDP-43 and argyrophilic grain disease compared to sAD; in the ADNI sAD cohort the latter two pathologies occurred in about 20% of subjects, while in the FAD DIAN cohort these pathologies were absent [18].”

    From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [18]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cairns, N. J., Perrin, R. J., Franklin, E. E., Carter, D., Vincent, B., Xie, M., Bateman, R. J., Benzinger, T., Friedrichsen, K., Brooks, W. S., Halliday, G. M., McLean, C., Ghetti, B., Morris, J. C., Initiative, T. A. D. N., & the Dominantly Inherited Alzheimer Network
Affiliations
  • Washington University in St. Louis (US)
  • UNSW Sydney (AU)
  • The University of Melbourne (AU)
  • Indiana University Indianapolis (US)
Corresponding author
Cairns, Nigel J.
Venue
Neuropathology
Publisher
Wiley
Published
2015-05-12
Volume
35
Issue
4
Pages
390-400
ISSN
  • 0919-6544 (ISSN-L)
  • 1440-1789
OpenAlex
W1490623534
Cited by
86
References
28
Citations by year
2026: 3 · 2025: 8 · 2024: 9 · 2023: 9 · 2022: 6 · 2021: 12 · 2020: 8 · 2019: 8 · 2018: 9 · 2017: 4 · 2016: 8 · 2015: 2
FWCI
5.59
Type
journal article
Language
en
Open access
Locations
  • Neuropathology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
  • PMC
Funders
  • National Institutes of Health (P50 AG05681, P01 AG03991, P01 AG26276, U01 AG032438, U01 AG024904, P30-NS048056)
  • ALzheimer's Association
  • AstraZeneca AB
  • Bristol-Myers Squibb
  • Eisai Global Clinical Development
  • Elan Corporation plc
  • Eli Lilly and Company
  • Forest Laboratories
  • GlaxoSmithKline
  • Institute for the Study of Aging
  • Merck and Co. Inc.
  • National Institute of Biomedical Imaging and Bioengineering
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • Wyeth Research
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
autosomal dominant Alzheimer's disease, late-onset Alzheimer's disease, autopsy, preclinical Alzheimer's disease, biomarkers, brain tissue
MeSH terms
Aged, 80 and over, Alzheimer Disease, Autopsy, Brain, Female, Humans, Male, Molecular Sequence Data, Organ Preservation, Tissue Banks, Biomarkers, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review